| [1] |
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin, 2018, 68(6): 394-424.
|
| [2] |
郑荣寿，孙可欣，张思维，等. 2015年中国恶性肿瘤流行情况分析 [J]. 中华肿瘤杂志，2019, 41(1): 19-28.
|
| [3] |
Gernaat SAM, Ho PJ, Rijnberg N, et al. Risk of death from cardiovascular disease following breast cancer: a systematic review [J]. Breast Cancer Res Treat, 2017, 164(3):537-555.
|
| [4] |
Armenian SH, Xu L, Ky B, et al. Cardiovascular disease among survivors of adult-onset cancer: a community-based retrospective cohort study [J]. J Clin Oncol, 2016, 34(10): 1122-1130.
|
| [5] |
Abdel-Qadir H, Austin PC, Lee DS, et al. A population-based study of cardiovascular mortality following early-stage breast cancer [J]. JAMA Cardiol, 2017, 2(1): 88-93.
|
| [6] |
Bradshaw PT, Stevens J, Khankari N, et al. Cardiovascular disease mortality among breast cancer survivors [J]. Epidemiology, 2016, 27(1): 6-13.
|
| [7] |
Abdel-Qadir H, Thavendiranathan P, Austin PC, et al. The risk of heart failure and other cardiovascular hospitalizations after early stage breast cancer: a matched cohort study [J]. J Natl Cancer Inst, 2019, 111(8): 854-862.
|
| [8] |
Jones LW, Haykowsky MJ, Swartz JJ, et al. Early breast cancer therapy and cardiovascular injury [J]. J Am Coll Cardiol, 2007, 50(15): 1435-1441.
|
| [9] |
Gulati M, Mulvagh SL. The connection between the breast and heart in a woman: breast cancer and cardiovascular disease [J]. Clin Cardiol, 2018, 41(2): 253-257.
|
| [10] |
Agunbiade TA, Zaghlol RY, Barac A. Heart failure in relation to anthracyclines and other chemotherapies[J]. Methodist Debakey Cardiovasc J, 2019, 15(4): 243-249.
|
| [11] |
Cardinale D, Ciceri F, Latini R, et al. Anthracycline-induced cardiotoxicity: a multicenter randomised trial comparing two strategies for guiding prevention with enalapril: the International CardioOncology Society-one trial [J]. Eur J Cancer, 2018, 94: 126-137.
|
| [12] |
Avila MS, Ayub-Ferreira SM, de Barros Wanderley MR Jr, et al. Carvedilol for prevention of chemotherapy-related cardiotoxicity: the CECCY Trial [J]. J Am Coll Cardiol, 2018, 71(20): 2281-2290.
|
| [13] |
Gradishar WJ, Anderson BO, Abraham J, et al. Breast cancer, version 3.2020, NCCN clinical practice guidelines in oncology [J]. J Natl Compr Canc Netw, 2020, 18(4): 452-478.
|
| [14] |
Dang CT, Yu AF, Jones LW, et al. Cardiac surveillance guidelines for trastuzumab-containing therapy in early-stage breast cancer: getting to the heart of the matter [J]. J Clin Oncol, 2016, 34(10): 1030-1033.
|
| [15] |
Bowles EJ, Wellman R, Feigelson HS, et al. Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study [J]. J Natl Cancer Inst, 2012, 104(17): 1293-1305.
|
| [16] |
Felker GM, Thompson RE, Hare JM, et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy [J]. N Engl J Med, 2000, 342(15): 1077-1084.
|
| [17] |
Mehta LS, Watson KE, Barac A, et al. Cardiovascular disease and breast cancer: where these entities intersect: a scientific statement from the American Heart Association [J]. Circulation, 2018, 137(8): e30-e66.
|
| [18] |
Rozner RN, Frishman WH. Cardiovascular effects of chemotherapy used in the treatment of breast cancers [J]. Cardiol Rev, 2019, 27(2): 87-96.
|
| [19] |
Darby SC, Ewertz M, McGale P, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer [J]. N Engl J Med, 2013, 368(11): 987-998.
|
| [20] |
Jacobse JN, Duane FK, Boekel NB, et al. Radiation dose-response for risk of myocardial infarction in breast cancer survivors [J]. Int J Radiat Oncol Biol Phys, 2019, 103(3): 595-604.
|
| [21] |
Lawrenson R, Lao C, Ali A, et al. Impact of radiotherapy on cardiovascular health of women with breast cancer [J]. J Med Imaging Radiat Oncol, 2019, 63(2): 250-256.
|
| [22] |
陈霞，罗凤. 乳腺癌患者辅助内分泌治疗依从性现状及对策的研究进展 [J/CD]. 中华乳腺病杂志(电子版), 2020, 14(2): 116-119.
|
| [23] |
Yao J, Deng K, Huang J, et al. Progress in the understanding of the mechanism of tamoxifen resistance in breast cancer[J]. Front Pharmacol, 2020, 11:592 912.
|
| [24] |
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials [J]. Lancet, 2005, 365(9472): 1687-1717.
|
| [25] |
Lai SW, Lin CL, Liao KF. Association between tamoxifen use and acute myocardial infarction in women with breast cancer [J]. Medicine (Baltimore), 2019, 98(3): e13925.
|
| [26] |
Khosrow-Khavar F, Filion KB, Al-Qurashi S, et al. Cardiotoxicity of aromatase inhibitors and tamoxifen in postmenopausal women with breast cancer: a systematic review and meta-analysis of randomized controlled trials [J]. Ann Oncol, 2017, 28(3): 487-496.
|
| [27] |
Matthews A, Stanway S, Farmer RE, et al. Long term adjuvant endocrine therapy and risk of cardiovascular disease in female breast cancer survivors: systematic review [J]. BMJ, 2018, 363: k3845.
|
| [28] |
Chamoto K, Al-Habsi M, Honjo T. Role of PD-1 in immunity and diseases [J]. Curr Top Microbiol Immunol, 2017, 410: 75-97.
|
| [29] |
Satouchi M, Nosaki K, Takahashi T, et al. First-line pembrolizumab vs chemotherapy in metastatic non-small-cell lung cancer: KEYNOTE-024 Japan subset [J]. Cancer Sci, 2020, 111(12): 4480-4489.
|
| [30] |
Jotte R, Cappuzzo F, Vynnychenko I, et al. Atezolizumab in combination with carboplatin and nab-paclitaxel in advanced squamous NSCLC (IMpower131): results from a randomized phase III trial [J]. J Thorac Oncol, 2020, 15(8): 1351-1360.
|
| [31] |
Lu S, Wang J, Cheng Y, et al. Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer: 2-year follow-up from a randomized, open-label, phase 3 study (CheckMate 078) [J]. Lung Cancer, 2021, 152:7-14.
|
| [32] |
Buisseret L, Garaud S, de Wind A, et al. Tumor-infiltrating lymphocyte composition, organization and PD-1/ PD-L1 expression are linked in breast cancer [J]. Oncoimmunology, 2016, 6(1): e1257452.
|
| [33] |
韩逸群，王佳玉，徐兵河. 晚期三阴性乳腺癌免疫检查点抑制剂联合靶向治疗进展 [J/CD]. 中华乳腺病杂志(电子版), 2020, 14(5): 261-265.
|
| [34] |
Mir H, Alhussein M, Alrashidi S, et al. Cardiac complications associated with checkpoint inhibition: a systematic review of the literature in an important emerging area [J]. Can J Cardiol, 2018, 34(8): 1059-1068.
|
| [35] |
Kumar V, Chaudhary N, Garg M, et al. Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy [J]. Front Pharmacol, 2017, 8: 49.
|
| [36] |
Johnson DB, Balko JM, Compton ML, et al. Fulminant myocarditis with combination immune checkpoint blockade [J]. N Engl J Med, 2016, 375(18): 1749-1755.
|
| [37] |
Mahmood SS, Fradley MG, Cohen JV, et al. Myocarditis in patients treated with immune checkpoint inhibitors [J]. J Am Coll Cardiol, 2018, 71(16): 1755-1764.
|
| [38] |
Escudier M, Cautela J, Malissen N, et al. Clinical features, management, and outcomes of immune checkpoint inhibitor-related cardiotoxicity [J]. Circulation, 2017, 136(21): 2085-2087.
|
| [39] |
Satija A, Spiegelman D, Giovannucci E, et al. Type 2 diabetes and risk of cancer [J]. BMJ, 2015, 350: g7707.
|
| [40] |
Flegal KM, Kit BK, Orpana H, et al. Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis [J]. JAMA, 2013, 309(1): 71-82.
|
| [41] |
陈叶飞，付笑影. 脂代谢在乳腺癌发生、发展及耐药中的作用机制 [J/CD]. 中华乳腺病杂志(电子版), 2020, 14(2): 112-115.
|
| [42] |
t’Kint de Roodenbeke MD, Pondé N, Buisseret L, et al. Management of early breast cancer in patients bearing germline BRCA mutations [J]. Semin Oncol, 2020, 47(5): 243-248.
|
| [43] |
van Westerop LL, Arts-de Jong M, Hoogerbrugge N, et al. Cardiovascular risk of BRCA1/2 mutation carriers: a review [J]. Maturitas, 2016, 91: 135-139.
|
| [44] |
Sajjad M, Fradley M, Sun W, et al. An exploratory study to determine whether BRCA1 and BRCA2 mutation carriers have higher risk of cardiac toxicity [J]. Genes (Basel), 2017, 8(2): 59.
|
| [45] |
Daly MB, Pal T, Berry MP, et al. Genetic/familial high-risk assessment: breast, ovarian, and pancreatic, version 2.2021, NCCN clinical practice guidelines in oncology [J]. J Natl Compr Canc Netw, 2021, 19(1): 77-102.
|
| [46] |
Zhang C, Shi D, Yang P. BNP as a potential biomarker for cardiac damage of breast cancer after radiotherapy: a meta-analysis [J]. Medicine (Baltimore), 2019, 98(29): e16507.
|
| [47] |
孙汶齐，袁丽君. 乳腺癌化疗相关心脏毒性的机制及其评估 [J/CD]. 中华乳腺病杂志(电子版), 2020, 14(3): 168-172.
|
| [48] |
Emaus MJ, Išgum I, van Velzen SGM, et al. Bragatston study protocol: a multicentre cohort study on automated quantification of cardiovascular calcifications on radiotherapy planning CT scans for cardiovascular risk prediction in patients with breast cancer [J]. BMJ Open, 2019, 9(7): e028752.
|